Sean Sheridan, in an article published in Law360, provides an overview of recent high-profile court cases that have addressed the issue of patentable subject matter. The article also describes how these decisions are changing patent examination at the U.S. Patent and Trademark Office and discusses how the changing scope of patent-eligible subject matter may impact intellectual property valuations and transactions in the life sciences field. To read the article, click the link below.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...